Skip to main content

Advertisement

Fig. 5 | BMC Research Notes

Fig. 5

From: Use of aminoglycoside 3′ adenyltransferase as a selection marker for Chlamydia trachomatis intron-mutagenesis and in vivo intron stability

Fig. 5

Growth phenotypes of DFCT9, DFCT13, and DFCT16 with and without ampicillin and/or spectinomycin. In panel a, L2 mouse cells were infected at an MOI ~5 with the wild type strain, DFCT9, DFCT13, or DFCT16 in the presence of no drug (top row), spectinomycin (second row from top), ampicillin (third row from top), or spectinomycin and ampicillin (fourth row from top). Resistance profiles and strain types are listed at the top of each row. Samples were processed for immunofluorescence microscopy at 24 h post infection. Cells were probed with anti-MOMP (green, marker for bacteria), anti-CT223 (red, inclusion membrane protein), and stained with DAPI (blue, DNA). Images were acquired at ×630 under oil-immersion and only the composite images are shown. In panel b, bla and aadA specific PCR was used to detect the resistance marker present in each strain. PCR products were visualized as described in Fig. 2

Back to article page